CONTEXT: A proper peer reviewed study article on a retrospective study based on an oncology registry in Canada highlighting the differences in outcomes for rural versus urban patients.
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 4
*1. “This article was originally published here. OBJECTIVE: The objective
of this study was to review real-world patterns of chemotherapy utilization
among patients with metastatic gastric/lower esophageal adenocarcinoma with
particular focus on the use of ramucirumab plus paclitaxel in previously
treated patients.” *
*2. “Multivariable logistic regression analysis was used to identify
factors associated with palliative chemotherapy use.” *
*3. “Within the subcohort of patients who received >1 line of chemotherapy,
use of ramucirumab/paclitaxel was associated with better OS (P=0.033).” *
*4. “Multivariable Cox regression analysis suggested that the following
factors are associated with better OS: use of ramucirumab/paclitaxel
(hazard ratio [HR]: 1.56; 95% CI: 1.07-2.29) and living within urban zones
including Calgary or Edmonton zones (vs. Northern zone) (HR for Calgary
zone vs. Northern zone: 0.44; 95% CI: 0.23-0.85; HR for Edmonton zone vs.
Northern zone: 0.41; 95% CI: 0.22-0.77).” *
*5. “CONCLUSIONS: Use of paclitaxel/ramucirumab combination beyond
first-line treatment is associated with improved OS among patients with
metastatic gastric/lower esophageal adenocarcinoma in this real-world
study.” *
Source URL:
https://www.docwirenews.com/abstracts/journal-abstracts/outcomes-of-ramucirumab-plus-paclitaxel-among-patients-with-previously-treated-metastatic-gastric-lower-esophageal-cancer-a-real-world-study-13/